|
|
|||||||
Malignant Lymphomas |
RIIIA and Fc
RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkins lymphoma patients treated with sequential CHOP and rituximabFrom the Divisione di Ematologia, Ospedali Riuniti Bergamo (EC, EO, SS, AR, JG, AR); CRUK Medical Oncology Laboratory, Barts and the London, Queen Mary School of Medicine and Dentistry, London, United Kingdom (EC); Dipartimento di Ematologia, Scienze Biomediche, Universita, Catania (GAP, DT); Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Rome, Italy (AP, RF)
Correspondence: Alessandro Rambaldi, M.D., USC Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy. E-mail: arambaldi{at}ospedaliriuniti.bergamo.it
We analyzed Fc
RIIIA-158V/F and Fc
RIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between Fc
RIIIA-158VV/VF and Fc
RIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.
Key words: Fc
R polymorphisms, follicular lymphoma, BCL2/IgH rearrangements.
This article has been cited by other articles:
![]() |
N. M. Pennell, T. Bhanji, L. Zhang, A. Seth, C. A. Sawka, and N. L. Berinstein Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma Haematologica, August 1, 2008; 93(8): 1265 - 1267. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |